ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Pharmaceutical company Ipsen acquires United States-based biotechnology firm Kartos Therapeutics in a deal valued at up to one point seven five billion dollars. The transaction expands Ipsens oncology portfolio by adding blood cancer treatments developed by the smaller startup entity.
Tap to vote and see what everyone thinks.
Summary by ByteBrief